Monoclonal antibody · Agonist of OX40 (CD134) (TNFRSF4) · developed by Genmab
GEN1055 is a hexabody-based agonistic monoclonal antibody that binds the co-stimulatory receptor OX40 (TNFRSF4) on T lymphocytes. Binding forms a hexamer that clusters OX40, promoting proliferation of memory and effector T cells and inhibiting regulatory T cells in the tumor microenvironment. It is being studied in malignant solid tumors.
Summary written with AI from the sources listed at the end of this page.
Malignant Solid Tumor
Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →